| ￥3000 | |
| Z05322-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 33.77 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 48-58 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of FSTL1, His, Human is greater than 95% as determined by SEC-HPLC »
FSTL1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Follistatin-like 1 (FSTL1), a secreted glycoprotein, has been shown to participate in regulating developmental processes and to be involved in states of disease and injury. Recent findings on FSTL1 in both acute coronary syndrome and heart failure emphasize its potential as a target for cardiac regenerative therapy. |
| Synonyms | Follistatin-related 1; Follistatin-like 1; FRP; FSL1; TSC-36; MIR198 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
